T9_IL-33 cells preserve GVL and antitumor activity. (A). Survival curves for BALB/c mice receiving 10⁴ syngeneic lymphoma cell line A20 cells with syngeneic T cells or allogeneic in vitro differentiated cells (n = 12 mice per group, from two independent experiments; ***, P < 0.0001, log-rank test). Pie charts show cause of death. (B) Survival curves for BALB/c mice receiving 10⁴ cells of the syngeneic MLL-AF9 leukemic cell line with syngeneic T cells or allogeneic in vitro differentiated cells (n = 12 mice per group, from two independent experiments; **, P < 0.01; ***, P < 0.001, log-rank test). Pie charts show cause of death. (C) Survival curves for C3H.SW mice receiving 10⁴ MLL-AF9 leukemic cells with syngeneic T9_IL-33 cells or allogeneic in vitro differentiated cells (n = 14 mice per group, from two independent experiments; ***, P < 0.001, log-rank test). Pie charts show cause of death. (D) Transcriptome analysis of Gzma, Gzmb, Prf1, Cd62l, Cd27, and Fas expression in sorted WT T9_IL-33 versus ST2^−/− T9_IL-33 CD8 and CD4 cells (n = 3; see Fig. S2). (E) Representative plots of Gzmb and Prf1 expression in WT T9_IL-33 and ST2^−/− T9_IL-33 cells gated on CD8, and bar graphs showing the frequency of GzmB⁺ and Prf1⁺ CD8 T cells (n = 8, from four independent experiments, unpaired t test; data are shown as mean ± SEM; **, P < 0.01). (F) Representative plots of GzmB and Prf1 expression in gated CD8 T cells from BM 28 d after adoptive transfer of allogeneic T cells with syngeneic MLL-AF9 cells. Bar graphs show the frequency of GzmB⁺ and Prf1⁺ CD8 T cells (n = 4, unpaired t test; data are shown as mean ± SEM; ***, P < 0.001).